Zealand Pharma (ZEAL.CO) Informs That Sanofi (France) (SAN.PA) Has Announced Initiation Of The Lixilan Phase 3 Clinical Program For The Fixed-Ratio Combination Of Lantus® And Lyxumia®
2/6/2014 9:38:41 AM
Copenhagen, 6 February 2014 – Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that Sanofi (EURONEXT: SAN and NYSE: SNY) in its Q4 2013 earnings released today, announced that the clinical Phase III development program for LixiLan has been started.
Help employers find you! Check out all the jobs and post your resume.
comments powered by